ACTA1 and Hepatic fibrosis: Treatment with GDC-0449 decreased α-sma-expressing myofibroblastic cells, hepatic expression of TGF-β and PDGF-β, Sirius red staining, and hydroxyproline content, demonstrating that Hh pathway inhibition reduced liver fibrosis (Figures 3C–D and Figures S3C–D).